Oxular

0 followers

‌

Oxular is developing disruptive treatments for retinal diseases. Oxular’s sustained-release formulations are engineered to last up to one year following single administration and perform in specific small spaces in the eye.

Industries

Headquarters

Employees

Links

Org chart

Thomas Cavanagh

Chief Executive Officer

Thomas Cavanagh

Collapse

Ronald Yamamoto

Chief Scientific Officer

Friedrich Asmus

Chief Medical Officer

Stacey Tucker

Finance Director

John Zemba

Director, Device Training

Paul Hawkins

Director of Information Management

Paul Pritchard

Associate Director of Procurement and Supply Chain

Seán Kearney

Director, Device Training

John Perry

Finance Director

Ken Macleod

Director

Jim Jogerst

Chief Business Officer

Teams

Business Development Team

11 members

Leadership Team

3 members

Clinical Operations Team

2 members

Similar companies

Synthekine

3 followers

Deep Science Ventures

2 followers

Autolus

1 follower

Caribou Biosciences

1 follower

Cargo

1 follower

Capricor Therapeutics

1 follower

Odyssey Therapeutics

2 followers

Cellares

2 followers

Avalere Health

3 followers

Thermo Fisher Scientific

149 followers

Gilead Sciences

121 followers

Discover companies